Therapeutic Indication

Foralumab Shows Imaging Signal in Progressive MS

Tiziana reported November 2 topline results from randomized, double-blind, placebo-controlled Phase 2a INFORM-MS in non-active secondary progressive multiple sclerosis. The 50-µg intranasal foralumab arm showed a TSPO-PET microglial-activation difference versus placebo at 12 weeks…

CTX310 Receives Two FDA RMAT Designations

In a November 2 disclosure recovered in the 36-hour window, CRISPR Therapeutics said FDA granted Regenerative Medicine Advanced Therapy (RMAT) designations to CTX310 for severe hypertriglyceridemia and elevated LDL-C. The company also reported third-quarter…

China Accepts First Line HER2 ADC Filing

China-originated regulatory signal: Hengrui disclosed on 29 October that NMPA accepted and placed its rezetecan trastuzumab application into priority review for first-line locally advanced or metastatic HER2-positive breast cancer, with or without pertuzumab. This…

China Accepts Sac TMT Lung Cancer Filing

China-source update: Kelun-Biotech’s Chinese-language newsroom listed on 28 October that CDE accepted a seventh sac-TMT indication filing for first-line PD-L1-negative, EGFR/ALK-negative nonsquamous NSCLC with pembrolizumab. The underlying Phase III OptiTROP-Lung06 data were reported earlier,…